...will now be reviewed by the European Commission which has the authority to approve medicines for the European Union. Bristol-Myers Squibb and AstraZeneca expect the European Commission to issue its decision on a Marketing Authorization for this type 2 diabetes...

Abstracts published online ahead of the International Society on Thrombosis and Hemostasis meeting in Boston later this month have provided some reassurance on the efficacy and safety profile of Pfizer/ Bristol-Myers Squibb's investigational Factor Xa

...plc (GSK) today announced that it has acquired the branded generics business of Bristol Myers Squibb (BMS) in Lebanon, Jordan, Syria, Libya and Yemen for a cash consideration of $23.2m (£14.2m). The business comprises a portfolio of 13 branded pharmaceuticals...

...that it preferred to see a third party to take a minority stake in the company and the likes of Pfizer, Roche, Lundbeck, Bristol-Myers Squibb and,most recently, Novartis, were linked with Elan. J&J has won the day, however, and Husseini Manji, head of neuroscience,...

...treatments include Humira from Abbott Laboratories (ABT), Remicade from Johnson & Johnson (JNJ) and Orencia from Bristol-Myers Squibb (BMY). Not far behind on the research program can be spotted the expensive tests for antibiotic-resistant staph germs, now...

...suitors had been touted as potential buyers for Elan or parts of its business, including Pfizer, Novartis and Bristol Myers Squibb, over the past year. Elan had come under pressure from a number of its shareholders to find a way forward for the business as...

...no matter how much in cost savings they can wring out of the acquisition. For the moment I’m still holding on to the Bristol Myers Squibb (BMY) position, as the valuation and yield are even more compelling than Pfizer was at the beginning of the year. But...

...30 days. Thank goodness. After months of soap-opera rumors, including potential deals with Pfizer (NYSE: PFE), Lundbeck, Bristol-Myers Squibb (NYSE: BMY), and Novartis (NYSE: NVS), we finally have a definitive close to Elan's (NYSE: ELN) strategic review. Apparently...

...$20 a share is PowerShares Dynamic Healthcare Sector Portfolio (PTH), an ETF featuring holdings such as Hospira (HSP), Bristol Myers Squibb (BMY) and Becton Dickinson (BDX). Unlike many existing health-care ETFs, which tend to be top-heavy in names like Merck...

...to call a global review caps off a big week of media account action that saw agency shifts by major players such as Bristol-Myers Squibb, Zurich Financial and LVMH. NEW YORK Unilever today said it has launched a global review that encompasses almost all...